Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat

J Neural Transm (Vienna). 2007;114(5):595-605. doi: 10.1007/s00702-006-0612-5. Epub 2006 Dec 21.

Abstract

The neuroprotective effects of intravenous rasagiline were investigated in a rat model of stroke. Middle cerebral artery (MCA) occlusion was performed in male rats and the short- (neurological severity score [NSS], infarct size), intermediate- (cognition) and long-term (necrotic area) effects were assessed. A bolus (3 mg/kg) of rasagiline followed by a 3-h infusion (3 mg/kg/h), initiated immediately after MCA occlusion, reduced infarct size by 48.6% and NSS by 32.7% relative to saline treatment. Cognitive function, tested in a water maze 2-3 weeks after occlusion, also significantly improved compared with saline-treated controls. Necrotic brain area was 35-50% smaller with rasagiline than with saline following a single bolus dose. The single bolus rasagiline dose was as effective as a rasagiline bolus followed by rasagiline infusion in short-term outcomes. The neuroprotective effect of rasagiline was fully reproducible when administered at 2 h following occlusion but not after 4 h.

MeSH terms

  • Animals
  • Brain Infarction / drug therapy*
  • Brain Infarction / pathology
  • Brain Infarction / physiopathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Brain Ischemia / physiopathology
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Cognition Disorders / physiopathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Indans / pharmacology*
  • Indans / therapeutic use
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Infarction, Middle Cerebral Artery / physiopathology
  • Male
  • Maze Learning / drug effects
  • Nerve Degeneration / drug therapy*
  • Nerve Degeneration / etiology
  • Nerve Degeneration / prevention & control
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Rats
  • Rats, Wistar
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Time Factors
  • Treatment Outcome

Substances

  • Indans
  • Neuroprotective Agents
  • rasagiline